Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hua Medicine Limited

Criteria

Inclusion Criteria:

• Male and female,age 18-65 years

• Has type 2 diabetes mellitus

• BMI 20 to 29kg/m2

• Willingness to adhere to the protocol requirement

Exclusion Criteria:

• Patients with type1 diabetes mellitus

• Received any antidiabetic drug within run-in or during screening

• Hepatic diseases

• Kidney diseases

• Clinical abnormal finding in EVG,labs and physical exams

• Women of child-bearing potential